Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa gets RMAT designation for new CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$126.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed\/Refractory Classical Hodgkin Lymphoma (cHL)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to \u2018Off-the-Shelf\u2019 CAR-T Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd Line Hodgkin Lymphoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Tessa Therapeutics

    Menu

    Tessa Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tessa Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd Line Hodgkin Lymphoma

              Details:

              TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.

              Lead Product(s): TT11X,Nivolumab,Fludarabine Phosphate

              Therapeutic Area: Oncology Product Name: TT11X

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute

              Details:

              Under terms of the CRADA, Tessa will collaborate with the NCI’s DCTD to identify potential opportunities to expand the applicability of TT11X, Tessa’s allogeneic off-the-shelf CD30.CAR-modified EBVST cell therapy, as a treatment of non-Hodgkin lymphoma.

              Lead Product(s): TT11X

              Therapeutic Area: Oncology Product Name: TT11X

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: National Cancer Institute

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodg...

              Details:

              The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). The CD30.CAR-T cell therapy was demonstrated to be well tolerated with no unexpected safety signals.

              Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride

              Therapeutic Area: Oncology Product Name: TT11

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform

              Details:

              TT11X (CD30.CAR-EBVST cells) utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas.

              Lead Product(s): CD30.CAR-EBVST Cells

              Therapeutic Area: Oncology Product Name: TT11X

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Baylor College of Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and...

              Details:

              TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.

              Lead Product(s): TT11X

              Therapeutic Area: Oncology Product Name: TT11X

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgki...

              Details:

              TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.

              Lead Product(s): Autologous CD30.CAR-T Cell Therapy,Nivolumab,Fludarabine Phosphate

              Therapeutic Area: Oncology Product Name: TT11

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022

              Details:

              TT11 – is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma.

              Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride

              Therapeutic Area: Oncology Product Name: TT11

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners

              Details:

              Tessa plans to use the proceeds from the financing to advance the ongoing clinical development of the company’s autologous CD30-CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X) programs.

              Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride

              Therapeutic Area: Oncology Product Name: TT11

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Polaris Partners

              Deal Size: $126.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

              Details:

              The PRIME designation was granted to TT11 by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center.

              Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride

              Therapeutic Area: Oncology Product Name: TT11

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tessa Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tessa gets RMAT designation for new CAR-T

              Details:

              The designation is based on the data of two independent Phase I/II trials, which show promising efficacy and strong safety profile of the therapy in Hodgkin lymphoma patients.

              Lead Product(s): CD30 CAR-T

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY